Key result
Heart rate-lowering therapies in cardiovascular disease act as a double-edged sword, presenting both potential clinical benefits and adverse risks.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Messerli et al. (2025) studied this question. Heart rate-lowering therapies in cardiovascular disease act as a double-edged sword, presenting both potential clinical benefits and adverse risks.
Synapse has enriched 10 related papers. Consider them for comparative context: